Biotech ETF Rises 17% in a Month Without NVIDIA
A biotech ETF posts a 17% gain in the trailing month even as NVIDIA weakens, underscoring a sector rotation that chal...
Before investing in 2023, it's vital to learn key concepts. Equip yourself with knowledge to ensure smart investment choices.
17,856 articlesA biotech ETF posts a 17% gain in the trailing month even as NVIDIA weakens, underscoring a sector rotation that chal...
OpenAI pursues a bold $1 trillion valuation as investors weigh hype against real-world profitability and a widening l...
Novo Nordisk faces challenges, but three strong catalysts could propel the stock higher. This article breaks down the...
Chinese firms are shifting away from Nvidia’s AI accelerators toward domestic suppliers, a move driven by policy aims...
Analysts say a terse, unhedged line buried in the FED minutes may be the strongest signal yet on future policy. Here’...
A new Fidelity analysis finds that most 401(k) savers reach the $100,000 mark in their early 40s. The article explain...
A sharp look at how Rivian Automotive and Tesla earn money, where their revenue comes from, and what the trends mean ...
Palantir's CEO used a televised interview to question AI pricing models, highlighting data ownership and sovereignty ...
July 2026 brings a fresh wave of opportunities in semiconductors. This guide reveals five names with durable demand, ...
Salesforce faces a growth hurdle in a fast-moving AI world. This article explains how a targeted acquisition could fi...
Suncor Energy has climbed sharply this year, but is the rally justified for new buyers? This guide breaks down the dr...
Investors are weighing two value plays: VLUE leans on the value factor itself, while VTV sticks with mega-cap, discou...